Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting
November 03 2022 - 9:00AM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, today announced
that a trial-in-progress abstract for the Company’s ongoing ANTLER
Phase 1 clinical trial evaluating CB-010 for relapsed or refractory
B cell non-Hodgkin lymphoma (r/r B-NHL) has been accepted as a
poster presentation at the 64th American Society of Hematology
(ASH) Annual Meeting, being held in New Orleans, Louisiana,
December 10-13, 2022.
The poster will provide details on the ANTLER clinical trial
design and objectives. Details of the poster presentation are as
follows:
Title: A First-in-Human Phase 1, Multicenter,
Open-Label Study of CB-010, a Next-Generation CRISPR-Edited
Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in
Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
(ANTLER Study)Presenter: Susan O’Brien, M.D.,
professor, Division of Hematology/Oncology and associate director
for clinical science, Chao Family Comprehensive Cancer Center,
University of California, Irvine, CA Session Name:
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster
IIISession Date: Monday, December 12,
2022Presentation Time: 6:00 pm - 8:00
pm CSTLocation: Ernest N. Morial Convention
Center, Hall D Abstract number: 4257
The poster presentation will be available for registered
attendees on the ASH website and on Caribou’s website Monday,
December 12, 2022 at 9:00 am CT.
About CB-010CB-010 is the lead product
candidate from Caribou’s allogeneic CAR-T cell therapy platform and
is being evaluated in patients with relapsed or refractory B cell
non-Hodgkin lymphoma (r/r B-NHL) in the ongoing ANTLER Phase 1
trial. CB-010 is an allogeneic anti-CD19 CAR-T cell therapy
engineered using Cas9 CRISPR hybrid RNA-DNA (chRDNA) technology to
insert a CD19-specific CAR into the TRAC gene and knock
out PD-1 to boost the persistence of antitumor activity. CB-010 is
the first allogeneic CAR-T cell therapy in the clinic with a PD-1
knockout. Additional information on the ANTLER trial can be found
at https://clinicaltrials.gov using identifier
NCT04637763.
About Caribou’s Novel Next-Generation CRISPR
PlatformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Class 2 CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems are
capable of editing unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”)
that direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.Caribou
Biosciences is a clinical-stage CRISPR genome-editing
biopharmaceutical company dedicated to developing transformative
therapies for patients with devastating diseases. The company’s
genome-editing platform, including its proprietary Cas12a chRDNA
technology, enables superior precision to develop cell therapies
that are specifically engineered for enhanced persistence. Caribou
is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell
therapies for the treatment of patients with hematologic
malignancies and solid tumors.
For more information about Caribou,
visit www.cariboubio.com and follow the company
@CaribouBio.
“Caribou Biosciences” and the Caribou logo are
registered trademarks of Caribou Biosciences, Inc.
Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, without limitation,
statements related to Caribou’s strategy, plans, and objectives,
and expectations regarding its clinical and preclinical development
programs, including its expectations relating to the timing of the
release of additional patient data from its ANTLER Phase 1 clinical
trial for CB-010. Management believes that these forward-looking
statements are reasonable as and when made. However, such
forward-looking statements are subject to risks and uncertainties,
and actual results may differ materially from any future results
expressed or implied by the forward-looking statements. Risks and
uncertainties include, without limitation, risks inherent in
development of cell therapy products, such as those associated with
being in the early stages of clinical development; uncertainties
related to the initiation, cost, timing, progress, and results of
Caribou’s current and future research and development programs,
preclinical studies, and clinical trials; and the risk that initial
or interim clinical trial data will not ultimately be predictive of
the safety and efficacy of Caribou’s product candidates or that
clinical outcomes may differ as more patient data becomes
available; as well as other risk factors described from time to
time in Caribou’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year
ended December 31, 2021, and subsequent filings. In light of the
significant uncertainties in these forward-looking statements, you
should not rely upon forward-looking statements as predictions of
future events. Except as required by law, Caribou undertakes no
obligation to update publicly any forward-looking statements for
any reason.
Caribou Biosciences, Inc.
Contacts:Investors:Amy Figueroa,
CFAafigueroa@cariboubio.com
Media:Peggy Vorwald,
Ph.D.pvorwald@cariboubio.com
Investors and Media:Elizabeth Wolffe, Ph.D., and Sylvia
WheelerWheelhouse
LSAlwolffe@wheelhouselsa.comswheeler@wheelhouselsa.com
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024